All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cancer Treatment Centers of America Selects Lyniate as Strategic Interoperability Solution, Putting Patients at the Center of Innovation

October 13th 2021

Corepoint Integration Engine chosen to Streamline Connectivity Across Care Teams, Affiliate Networks, and Cancer Community, Extending Access to World-class Care for Patients Everywhere.

IO Combo Anchors a New Front Line Taking Shape in Unresectable HCC

October 13th 2021

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

FDA Approves Pembrolizumab Plus Chemo With or Without Bevacizumab for Frontline Cervical Cancer

October 13th 2021

The FDA has approved pembrolizumab for use in combination with chemotherapy, with or without bevacizumab, in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher, as determined by an FDA-approved test.

Analysis Examines Real-World Survival Outcomes With Frontline Combos in Metastatic RCC

October 13th 2021

The 18-month survival rates observed with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in the frontline treatment of patients with metastatic renal cell carcinoma were not found to be statistically different.

FDA Approves Adjuvant Abemaciclib Plus Endocrine Therapy for Select HR+ Early Breast Cancer

October 13th 2021

The FDA has approved abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20% or higher, as determined by an FDA-approved test.

Expanding Armamentarium Underscores the Importance of Close Monitoring in Urothelial Cancer

October 12th 2021

With new therapeutic options, such as enfortumab vedotin-ejfv and, available to treat patients with locally advanced or metastatic urothelial cancer who require second- or third-line therapy, early detection of disease progression is critical.

Trastuzumab Duocarmazine Produces PFS Benefit in Pretreated HER2+ Breast Cancer

October 12th 2021

Vic-trastuzumab duocarmazine markedly improved progression-free survival vs physician’s choice of treatment in patients with HER2-positive metastatic breast cancer who had received 2 prior treatment regimens or ado-trastuzumab emtansine in the metastatic setting, according to data from the phase 3 TULIP trial.

FDA Type A Meeting Informs Next Steps for Oral Paclitaxel/Encequidar in Metastatic Breast Cancer

October 12th 2021

Following a Type A meeting with the FDA to discuss deficiencies raised in a complete response letter pertaining to the new drug application for the use of oral paclitaxel encequidar in patients with metastatic breast cancer, the biopharmaceutical company Athenex, Inc. announced that their resources will be redeployed to focus on other studies examining oral paclitaxel.

Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC

October 12th 2021

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

The US Oncology Network Announces Trusted Leader Jason Hammonds as New President

October 12th 2021

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that it has appointed Jason Hammonds as its new president.

FDA Lifts Hold on Rusfertide Clinical Development Program

October 12th 2021

The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide.

Challenges to Scientific Expertise: Future Implications for Oncology

October 12th 2021

The continued uncertainties of the current and future status of the COVID-19 pandemic have resulted in a lack of trust in the authority of the scientific establishment in the United States, and elsewhere, as it operates during these difficult times.

Chemotherapy-Free Options Expand the Scope of Treatment in Leukemia and Lymphoma

October 12th 2021

Across the paradigms of leukemias and lymphomas, novel therapies—such as BTK inhibitors, PI3K inhibitors, time-limited therapies, and even CAR T-cell therapies—have transformed the treatment of patients and prolonged survival without the need for chemotherapy.

Nivolumab/Cabozantinib Continues to Showcase Deep, Durable Responses in Advanced RCC

October 11th 2021

Nivolumab plus cabozantinib continued to significantly improve overall response rate vs sunitinib in patients with previously untreated, advanced renal cell carcinoma, with meaningful response outcomes observed irrespective of dose modifications with cabozantinib and fewer responders in the doublet arm requiring subsequent treatment.

Sarah Cannon Research Institute Experts Pinpoint Open Clinical Trials in Tennessee

October 11th 2021

Spanning metastatic non–small cell lung cancer, castration-resistant prostate cancer, and HER2-low breast cancer, here are 4 must-know clinical trials in Tennessee that community oncologists can now enroll their patients on.

Autologous HSCT Shows Sustained Long-Term Benefit in MCL, But Role May Be Rechallenged By Novel Approaches

October 11th 2021

Autologous hematopoietic stem-cell transplantation maintained its long-term efficacy over interferon alfa in patients with mantle cell lymphoma, confirming its place as the standard frontline treatment in this population.

Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22

October 11th 2021

The Boston Society in collaboration with Harvard Medical School is bringing together the top Acute Myeloid Leukemia (AML) experts for a power-packed one day conference to deliberate upon AML from varied perspectives.

Research Project Aims to Make CAR-T-cell Therapy Safer and More Effective

October 11th 2021

A new project led by researchers at MUSC Hollings Cancer Center could significantly decrease the side effects associated with CAR-T-cell therapy and make the treatment available to more patients who could benefit.

Find the Job That’s Right for You

October 11th 2021

The American Society of Clinical Oncology projects significant shortages of practicing oncologists compared with patients with new cancer diagnoses and existing cancer by 2025.

Novel Drug Sparks Hope for Targeting HER3 in NSCLC and Beyond

October 11th 2021

Patritumab deruxtecan, a novel antibody-drug conjugate, is emerging as a promising HER3-directed therapy in patients with non–small cell lung cancer and perhaps other solid malignancies.